Ramón Corbalán

Ramón Corbalán

Auto-generated profile, based on publicly available information

Ramón Corbalán

Pontificia Universidad Católica de Chile, Chile

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
RCRamon Corbalan
Ramon Corbalan
JBJean-Pierre Bassand
Jean-Pierre Bassand
LILaura Illingworth
Laura Illingworth
GAGiuseppe Ambrosio
Giuseppe Ambrosio
ACA. John Camm
A. John Camm
FIfor the GARFIELD-AF Investigators
for the GARFIELD-AF Investigators
Congestive heart failure (CHF) is commonly associated with atrial fibrillation (AF), and their combined presentation confers a worse prognosis than either condition alone.1 Treatment of both conditions implies use of specific drugs for CHF plus antithrombotic agents for stroke prevention. In addition, management strategies and outcomes may be affected by the etiology of CHF, namely ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM) because the prescription of antithrombotic therapies might be different and could affect prognosis in terms of death, stroke/systemic embolism (SE), and bleeding.2,3 The aim of our study was to assess the treatment strategies in terms of antithrombotic and CHF therapies and 1-year clinical outcomes in patients with newly diagnosed AF and concomitant CHF stratified by etiology (ICM vs NICM) enrolled in the Global Anticoagulant Registry in the Field–Atrial Fibrillation (GARFIELD-AF) registry.

23 September 2015 in Echocardiography
Verified
Journal Article
Closed access
PDF file
HVHugo E. Verdejo
Hugo E. Verdejo
EBElia Becerra
Elia Becerra
RZRicardo Zalaquet
Ricardo Zalaquet
ACAndrea del Campo
Andrea del Campo
LGLorena Garcia
Lorena Garcia
RCRamón Corbalán
Ramón Corbalán

1 August 2001 in The American Journal of Cardiology
Verified
Journal Article
Closed access
RCRamón Corbalán
Ramón Corbalán
GLGermán Larrain
Germán Larrain
CNCarolina Nazzal
Carolina Nazzal
PCPablo F Castro
Pablo F Castro
MAMónica Acevedo
Mónica Acevedo
MKMitchell W Krucoff
Mitchell W Krucoff

23 March 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SSScott D Solomon
Scott D Solomon
BCBrian L Claggett
Brian L Claggett
ZMZi Michael Miao
Zi Michael Miao
RDRafael Diaz
Rafael Diaz
GFG Michael Felker
G Michael Felker
JTJohn R Teerlink
John R Teerlink
In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction. We explored the influence of atrial fibrillation or flutter (AFF) on the effectiveness of omecamtiv mecarbil. GALACTIC-HF enrolled patients with New York Heart Association (NYHA) Class II–IV heart failure, left ventricular ejection fraction ≤35%, and elevated natriuretic peptides. We assessed whether the presence or absence of AFF, a pre-specified subgroup, modified the treatment effect for the primary and secondary outcomes, and additionally explored effect modification in patients who were or were not receiving digoxin. Patients with AFF (n = 2245, 27%) were older, more likely to be randomized as an inpatient, less likely to have a history of ischaemic aetiology or myocardial infarction, had a worse NYHA class, worse quality of life, lower estimated glomerular filtration rate, and higher N-terminal pro-B-type natriuretic peptide. The treatment effect of omecamtiv mecarbil was modified by baseline AFF (interaction P = 0.012), with patients without AFF at baseline deriving greater benefit. The worsening of the treatment effect by baseline AFF was significantly more pronounced in digoxin users than in non-users (interaction P = 0.007); there was minimal evidence of effect modification in those patients not using digoxin (P = 0.47) or in digoxin users not in AFF. Patients in AFF at baseline were less likely to benefit from omecamtiv mecarbil than patients without AFF, although the attenuation of the treatment effect was disproportionally concentrated in patients with AFF who were also receiving digoxin. Clinical Trial Registration: NCT02929329 In GALACTIC-HF, patients with atrial fibrillation or flutter (AFF) at baseline derived less benefit from Omecamtiv Mecarbil than patients not in AFF. This finding was primarily driven by those patients in AFF who were taking digoxin.

4 February 1998 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RERoberto Ebensperger
Roberto Ebensperger
EAErika Acevedo
Erika Acevedo
JMJaime Meléndez
Jaime Meléndez
RCRamón Corbalán
Ramón Corbalán
MAMónica Acevedo
Mónica Acevedo
SLSergio Lavandero
Sergio Lavandero

21 July 2020 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
MAMónica Acevedo
Mónica Acevedo
GVGiovanna Valentino
Giovanna Valentino
MBMaría José Bustamante
María José Bustamante
LOLorena Orellana
Lorena Orellana
MAMarcela Adasme
Marcela Adasme
CNCarlos Navarrete
Carlos Navarrete
Background: Cardiorespiratory fitness (CRF) is a powerful predictor of mortality. This study evaluated the predictive value of CRF for mortality in Chilean subjects without atherosclerotic disease compared with the Framingham, European Systematic Coronary Risk Evaluation (SCORE), and 2013 ACC/AHA risk scores and determined the incremental predictive value of CRF when added to these scores.Hypothesis: CRF improves prediction of all‐cause and cardiovascular disease (CVD)‐related mortality of the standard international risk scores.Methods: Cross‐sectional study, which evaluated 4064 subjects between 2002 and 2016. Cardiovascular (CV) risk factors, anthropometric and biochemical parameters, and blood pressure were measured. CRF was determined by metabolic equivalents during maximum stress test. The Framingham, SCORE, and ACC/AHA risk scores were calculated for all subjects. After a median follow‐up of 9 years, all‐cause and CVD‐related mortality were assessed. Receiver operating curves were built to determine mortality prediction for CRF, the risk scores, and CRF added to the scores.Results: As of August 2016, 99 deaths were reported, 33 of which were CVD‐related. All risk scores and CRF predicted CVD‐related mortality, with CRF identified as the best predictor: CRF: C = 0.88 (95% CI: 0.82‐0.93) vs Framingham: C = 0.68 (95% CI: 0.60‐0.76), SCORE: C = 0.76 (95% CI: 0.70‐0.83), and ACC/AHA: C = 0.79 (95% CI: 0.73‐0.85). Predictive power of the three scores improved when CRF was added to the model, but this was only significant for the Framingham score.Conclusions: CRF is a good predictor of both, all‐cause and CV mortality and a better predictor of CVD‐related deaths than standard risk scores in this population.